Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
284 studies found for:    "Scleroderma, Systemic"
Show Display Options
Download search resultsDownload the search results for:
"Scleroderma, Systemic" (284 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Completed
Has Results
Pulmonary Involvement in Scleroderma: A Clinical Study of the Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients With Lung Involvement
Condition: Scleroderma, Systemic
Intervention: Drug: Mycophenolate mofetil
2 Completed Efficacy and Safety Study of GB-0998 for Treatment of Systemic Sclerosis
Condition: Scleroderma, Systemic
Intervention: Drug: High-dose intravenous immunoglobulin (Venoglobulin-IH)
3 Terminated Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis
Condition: Scleroderma, Systemic
Interventions: Drug: Thalidomide;   Drug: Placebo thalidomide
4 Recruiting A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis
Condition: Scleroderma, Systemic
Interventions: Drug: Nintedanib;   Drug: Placebo
5 Completed
Has Results
Imatinib in Systemic Sclerosis
Condition: Scleroderma, Systemic
Intervention: Drug: Imatinib mesylate
6 Not yet recruiting Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis
Condition: Scleroderma, Systemic
Interventions: Drug: GSK2330811;   Drug: Placebo
7 Recruiting Role of Circulating Cytotoxic Lymphocytes in Endothelial Cell Injury in Systemic Sclerosis
Condition: Scleroderma, Systemic
Intervention: Other: blood samples
8 Active, not recruiting Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
Condition: Scleroderma, Systemic
Interventions: Drug: Riociguat (Adempas, BAY63-2521);   Drug: Placebo
9 Not yet recruiting The Clinical And Subclinical Effects on Arterial Stiffness of Bosentan in Patients With Systemic Sclerosis
Condition: Scleroderma, Systemic
Intervention: Drug: bosentan
10 Unknown  Platelet Gel in Systemic Sclerosis
Condition: Scleroderma, Systemic
Intervention: Drug: Platelet Gel
11 Recruiting Subcutaneous Injection of Autologous Adipose Tissue-derived Stromal Vascular Fraction Into the Fingers of Patients With Systemic Sclerosis
Condition: Scleroderma, Systemic
Interventions: Drug: Stromal Vascular fraction;   Drug: Ringer lactate
12 Not yet recruiting Treprostinil Iontophoresis in Systemic Sclerosis Digital UlcErations. A Proof of Concept Study
Condition: Scleroderma, Systemic
Interventions: Drug: Iontophoresis of treprostinil;   Drug: Iontophoresis of placebo
13 Completed Efficacy and Safety of Imatinib in Scleroderma
Conditions: Scleroderma, Localized;   Scleroderma, Systemic
Intervention: Drug: imatinib mesylate
14 Unknown  Oral Manifestations of Systemic Sclerosis
Condition: Scleroderma, Systemic
Intervention: Radiation: Cone Beam Computed Tomography (CBCT)
15 Recruiting Scleroderma Registry & Repository at the Hospital for Special Surgery
Condition: Scleroderma
Intervention:
16 Unknown  Nilotinib in the Treatment of Systemic Sclerosis
Condition: Systemic Sclerosis
Intervention: Drug: Nilotinib (Tasigna)
17 Active, not recruiting Taking Charge of Systemic Sclerosis
Condition: Scleroderma
Interventions: Other: Internet-based self-management program;   Other: Scleroderma book
18 Completed Morbidity and Mortality Follow Up for the Scleroderma Lung Study
Condition: Scleroderma
Intervention: Other: Followup survey
19 Unknown  Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis
Condition: Systemic Sclerosis
Intervention: Drug: Imatinib Mesylate
20 Completed Angiogenic/Angiostatic Mediators in Patients With Systemic Sclerosis
Condition: Systemic Sclerosis
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.